MAP2K7 and cancer: When MEK inhibitors are combined with traditional chemotherapeutic agents, drug scheduling may have a critical disease management role because MEK inhibitors cause cell cycle arrest whereas many standard cytotoxic agents kill actively dividing cancer cells [46, 48].